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routine screening for asymptomatic carotid artery stenosis.
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Reply
We appreciate the opportunity to respond to the letter
of Dr Norris et al. We would, however, like to clarify some
of their concerns. The interest in carotid angioplasty and
the impetus for a randomized trial is surprisingly wide-
spread. Thus, we have concerns about the issue of carotid
angioplasty and stenting. Dr Norris did not completely
state our conclusions that "we do not support further clin-
ical investigation in a randomized fashion."l We do agree
that further clinical investigation may be necessary, but
there is no uncertainty in our minds about the differences
in these two therapeutic methods. When considering the
"equipoise of clinical research," the surgeons at the
University ofAlabama at Birmingham do not have "a state
of genuine uncertainty... regarding the comparative thera-
peutic merits" of these two forms of therapy.2 Therefore,
we ask why these authors would consider a trial if they
agree that percutaneous transluminal angioplasty with
stenting is not an acceptable alternative to carotid
endarterectomy?
I also would like to further clarify other points in this let-
ter. All ofthe patients who were symptomatic in the Alabama
series were not "rejected for surgery." Approximately 40% to
45% of the patients were referred by surgeons, most of
whom work outside of our institution. Less than 10% of the
patients who underwent treatment with carotid angioplasty
and stenting in this series were referred by these authors. Of
note, from our previous reports, more patients were refused
for angioplasty and stenting and ultimately underwent surgi-
cal therapy than crossover from the surgical to medical side.
We wholeheartedly agree that this new procedure
should be evaluated on a "scientific footing" as Dr Norris
comments. However, to state that the only valid scientific
evaluation is done in a randomized prospective clinical
trial is foolish and unwise. Our scientific knowledge is not
limited to randomized prospective trials, as some would
have us believe. If a randomized prospective trial was
undertaken with 600 patients, please consider the follow-
ing outcomes: with the stroke rate of these authors of
18%, 300 randomized patients would have 54 strokes. If
one considers the recently reported 2.67% stroke rate of
the largest clinical report of carotid endarterectomy in
patients who were symptomatic,3 then there would be
eight strokes in a randomized group of 300 patients. By
that calculation, 46 people are inappropriately exposed to
stroke because of our scientific community's inability to
make an appropriate judgement about a new therapy with-
out the benefit of a randomized clinical trial. We consider
that an inappropriate risk.
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We would ask, instead, that carotid physicians
throughout the world not be blinded by the fallacy that
clinical information is only obtained in randomized clini-
cal trials.
William D. Jordan, Jr, MD
David C. Voellinger, MD
Winfield S. Fisher, MD
Holt A. McDowell, MD
Department of Surgery and Biostatistics
University ofAlabama at Birmingham
Birmingham, Ala
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Regarding "Aortoiliac stent deployment versus
surgical reconstruction: analysis of outcome and cost"
To the Editors:
I read with interest the article by Jeffrey L. Ballard and
colleagues (J Vasc Surg 1998;28:94-103), and it was clear
to me that the data presented contained significant flaws.
Besides patient selection bias, the patency rate and cost
analysis was skewed to heavily favor surgery over stent
deployment. It is notable that although one half of the
cases were performed by interventional radiologists, none
were included in the author list.
This consecutive, nonrandomized study resulted in
the surgery group having a significantly higher percentage
ofpatients with better runoff vessels. For instance, 70% of
the surgery group had a patent superficial femoral artery,
with 54% with three-vessel tibial runoff, as compared with
56% and 38%, respectively, for the stent group. The
surgery group had a one-vessel tibial runoff in only 8% of
the cases as compared with 30% for the stent group. The
disparity heavily favors the surgery group. To quote the
authors of the article, "Compromised infrainguinal runoff
has been noted to have an adverse affect on long-term
aortofemoral bypass graft patency, as well as on stented
iliac artery patency." This fact may have contributed to the
higher patency rates reported for the surgery group. In
addition, in their calculations, the authors excluded
patients with category 1 aortoiliac disease who underwent
treatment with stent deployment. These patients tend to
have high long-term patency rates, and, by this exclusion,
the patency rates again heavily favor the surgery group.
The authors conclude that surgical revascularization
should be the benchmark for cost-effective treatment of
